{"disease":{"id":"acute-lymphocytic-leukaemia-refractory","name":"acute lymphocytic leukaemia refractory"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05086315","title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":101,"lead_sponsor_name":"Sanofi","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}